Reduced Expression Level of SHP1 Gives An Additive Survival Advantage to the Ph plus Cells of Chronic Myeloid Leukemia (CML) Patients and Provides a Novel Pretreatment Predictor of Major Molecular Response Achievement in CML Patients

Authors :: Esposito, N
Quintarelli, C
Colavita, I
Izzo, B
Peluso, AL
Ruoppolo, M
Del Vecchio, L
Russo, D
Branford, S
Iacobucci, I
Thornquist, M
Barnett, M
Melo, J
Saglio, G
Radich, J
Peter, L
Martinelli, G
Kalebic, T
Hughes, T
Pane, F
Source :: (2010)., info:cnr-pdr/source/autori:Esposito, N; Quintarelli, C; Colavita, I; Izzo, B; Peluso, AL; Ruoppolo, M; Del Vecchio, L; Russo, D; Branford, S; Iacobucci, I; Thornquist, M; Barnett, M; Melo, J; Saglio, G; Radich, J; Peter, L; Martinelli, G; Kalebic, T; Hughes, T; Pane, F/titolo:Reduced Expression Level of SHP1 Gives An Additive Survival Advantage to the Ph plus Cells of Chronic Myeloid Leukemia (CML) Patients and Provides a Novel Pretreatment Predictor of Major Molecular Response Achievement in CML Patients/doi:/rivista:/anno:2010/pagina_da:/pagina_a:/intervallo_pagine:/volume
Publication Year :: 2010

Database :: OpenAIRE
Journal :: (2010)., info:cnr-pdr/source/autori:Esposito, N; Quintarelli, C; Colavita, I; Izzo, B; Peluso, AL; Ruoppolo, M; Del Vecchio, L; Russo, D; Branford, S; Iacobucci, I; Thornquist, M; Barnett, M; Melo, J; Saglio, G; Radich, J; Peter, L; Martinelli, G; Kalebic, T; Hughes, T; Pane, F/titolo:Reduced Expression Level of SHP1 Gives An Additive Survival Advantage to the Ph plus Cells of Chronic Myeloid Leukemia (CML) Patients and Provides a Novel Pretreatment Predictor of Major Molecular Response Achievement in CML Patients/doi:/rivista:/anno:2010/pagina_da:/pagina_a:/intervallo_pagine:/volume
Accession number :: edsair.cnr...........47cd186e46120b39f9d24cafa8af0568

Tools